Aptamers Versus Vascular Endothelial Growth Factor (VEGF): A New Battle against Ovarian Cancer
Pharmaceuticals · 06.06.2023 · 16 (6) · 849
DOI: 10.3390/ph16060849 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 06.06.2023. Verfasst von Yachana Mishra und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Bioengineering and Biosciences, Lovely Professional University, Phagwara 144411, Punjab, India. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cancer is one of the diseases that causes a high mortality as it involves unregulated and abnormal cell growth proliferation that can manifest in any body region. One of the typical ovarian cancer symptoms is damage to the female reproductive system. The death rate can be reduced through early detection of the ovarian cancer. Promising probes that can detect ovarian cancer are suitable aptamers. Aptamers, i.e., so-called chemical antibodies, have a strong affinity for the target biomarker and can typically be identified starting from a random library of oligonucleotides. Compared with other probes, ovarian cancer targeting using aptamers has demonstrated superior detection effectiveness. Various aptamers have been selected to detect the ovarian tumor biomarker, vascular endothelial growth factor (VEGF). The present review highlights the development of particular aptamers that target VEGF and detect ovarian cancer at its earliest stages. The therapeutic efficacy of aptamers in ovarian cancer treatment is also discussed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Bioengineering and Biosciences, Lovely Professional University, Phagwara 144411, Punjab, India.
- School of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411, Punjab, India.
- Lincoln Medical School, University of Lincoln, Brayford Pool, Lincoln LN6 7TS, UK.
ORCID-Profile: Yachana Mishra, Vijay Mishra, Abhigyan Ranjan, Murtaza M Tambuwala
Zitieren
APA
Mishra, Y., Chattaraj, A., Mishra, V., Ranjan, A., & Tambuwala, M. M. (2023). Aptamers Versus Vascular Endothelial Growth Factor (VEGF): A New Battle against Ovarian Cancer. Pharmaceuticals, 16(6), 849. https://doi.org/10.3390/ph16060849
Vancouver
Mishra Y, Chattaraj A, Mishra V, Ranjan A, Tambuwala MM. Aptamers Versus Vascular Endothelial Growth Factor (VEGF): A New Battle against Ovarian Cancer. Pharmaceuticals. 2023;16(6):849. doi:10.3390/ph16060849
BibTeX
@article{Mishra2023,
author = {Mishra, Yachana and Chattaraj, Aditi and Mishra, Vijay and Ranjan, Abhigyan and Tambuwala, Murtaza M},
title = {Aptamers Versus Vascular Endothelial Growth Factor (VEGF): A New Battle against Ovarian Cancer},
journal = {Pharmaceuticals},
year = {2023},
volume = {16},
number = {6},
pages = {849},
doi = {10.3390/ph16060849}
}
EUVIMED